KDM4C and myeloproliferative neoplasm: Quantification of JMJD2C protein expression from n = 26 MPN patients and n = 9 healthy controls (HC) revealed significantly elevated JMJD2C protein levels in patients with essential thrombocythemia, polycythemia vera and primary myelofibrosis (Fig. 1H, I).